CADL

Candel Therapeutics, Inc.

1.75 USD
+0.05 (+2.94%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Candel Therapeutics, Inc. stock is up 32.58% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 March’s closed higher than February.

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer. CAN-3110, in Phase I clinical trials for the. treatment of recurrent glioblastoma, has completed Phase Ib/II clinical trials.